Emtricitabine and Tenofovir Market Growing Rapidly by 2031 - Gilead Sciences, Cipla & Mylan Pharmaceuticals.

The Emtricitabine/Tenofovir market is projected to grow at a compound annual growth rate (CAGR) of 5% during the forecast period from 2024 to 2031.

Emtricitabine/Tenofovir, marketed under the brand name Truvada, is a fixed-dose combination antiretroviral medication used for the treatment and prevention of HIV/AIDS. This combination consists of two antiretroviral drugs: Emtricitabine, a nucleoside reverse transcriptase inhibitor (NRTI), and Tenofovir disoproxil, a nucleotide reverse transcriptase inhibitor (NtRTI). Together, these medications work by inhibiting the enzyme reverse transcriptase, which is essential for viral replication in the body.

While Truvada is highly effective in managing HIV infection, it must be used in combination with other antiretroviral medications to fully suppress the virus. In addition to its role in treatment, Truvada is also widely used as a pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection in high-risk individuals, making it a cornerstone of HIV prevention strategies worldwide.

Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/emtricitabine-and-tenofovir-market

Market Trends:

An increase in the number of HIV/AIDS patients will drive the market.

Human immunodeficiency virus (HIV) targets the immune system, weakening the body's defense against various infections and certain cancers that a healthy immune system would typically fend off. The combination of Emtricitabine and Tenofovir (marketed as Descovy and Truvada) is used alongside other medications to treat HIV in adults and children weighing at least 37 pounds (17 kg). Additionally, Truvada is prescribed in combination with safer sex practices, like Safety use, to reduce the risk of HIV infection in high-risk adults and teenagers weighing at least 77 pounds (35 kg). Both Emtricitabine and Tenofovir belong to the class of nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), which slow the spread of HIV in the body.

HIV remains a significant global public health issue, having claimed approximately 34.7 million lives to date. The market growth for Emtricitabine/Tenofovir is expected to be driven by increasing drug approvals.
The range of available antiretroviral (ARV) drugs has expanded, with approvals of novel ARVs featuring new mechanisms of action and combination tablets of existing medications, such as Emtricitabine/Tenofovir.

Market Segmentation:

By Type: Outsourcing of API, Self-production API.

By Application: Hospitals, Clinics, Others.

Get Customization in the report as per your requierments: https://datamintelligence.com/customize/emtricitabine-and-tenofovir-market

Major Key Players:

• Gilead Sciences
• Cipla
• Mylan Pharmaceuticals
• Emcure Pharmaceuticals
• Hetero Drugs
• Sun Pharmaceutical Industries
• Alkem Laboratories
• Hengrui Medicine
• SYSVAX
• Hisun Pharmaceutical

Product Portfolio:

Overview: Gilead Sciences, Inc., based in Foster City, California, is an American biopharmaceutical company specializing in the research and development of antiviral drugs for treating HIV, hepatitis B, hepatitis C, and influenza, including well-known medications like Harvoni and Sovaldi. The company is committed to creating innovative treatments for severe and life-threatening illnesses. Gilead's management strategy focuses on fostering a sustainable future, driven by a dedication to integrity and excellence.

Regional Analysis:

The global Emtricitabine and Tenofovir Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The Emtricitabine and Tenofovir Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications.

Related Reports:

Semen Analysis Market: https://datamintelligence.com/research-report/semen-analysis-market

Pediatric Ventilators Market: https://datamintelligence.com/research-report/pediatric-ventilators-market

Affiliate Marketing Request here: https://www.datamintelligence.com/affiliate-marketing

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.